3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 4
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
6
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Prostatic Neoplasms
1
Plasmacytoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Melanoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Immunoglobulin Light-chain Amyloidosis
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Interventions
Dexamethasone
7
daratumumab
3
Peripheral Blood Stem Cell Transplantation
3
Calcium Dobesilate
3
venetoclax
2
pomalidomide
2
ixazomib
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Mycophenolic Acid
2
Lenalidomide
2
Cyclosporine
2
Cyclophosphamide
2
ethanolamine oleate
1
dexamethasone acetate
1
carfilzomib
1
birtamimab
1
belantamab mafodotin
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Thalidomide
1
Sulfamethoxazole
1
Sodium Chloride
1
Saline Solution, Hypertonic
1
Saline Solution
1
Phenytoin
1
Pentetic Acid
1
Methotrexate
1
Melphalan
1
In Situ Hybridization, Fluorescence
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Immunoglobulin Light-chain Amyloidosis
×
Thalidomide
×
Clear all
NCT02545907
2021-04-15
CATALYST
University College, London
Phase 1/2
Completed
10 enrolled
14 charts